NR2F6, a new immune checkpoint that acts as a potential biomarker of immunosuppression and contributes to poor clinical outcome in human glioma

INTORODUCTION: Nuclear receptor subfamily 2 group F member 6 (NR2F6) is a promising checkpoint target for cancer immunotherapy. However, there has been no investigation of NR2F6 in glioma. Our study systematically explored the clinical characteristics and biological functions of NR2F6 in gliomas. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Miftah, Hayat, Naji, Oumayma, Ssi, Saadia Ait, Ghouzlani, Amina, Lakhdar, Abdelhakim, Badou, Abdallah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419227/
https://www.ncbi.nlm.nih.gov/pubmed/37575237
http://dx.doi.org/10.3389/fimmu.2023.1139268

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419227/
https://www.ncbi.nlm.nih.gov/pubmed/37575237
http://dx.doi.org/10.3389/fimmu.2023.1139268

Ejemplares similares